Bruker Corporation — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This is an annual filing; it does not provide a standalone fourth-quarter financial summary. Bruker develops and sells scientific instruments, analytical and diagnostic solutions, and superconducting materials through four segments: BSI BioSpin, BSI CALID, BSI Nano and BEST.
Financial performance
| Metric | FY2023 | FY2022 | Change |
|---|---|---|---|
| Revenue | $2,964.5 million | $2,530.7 million | +17.1%; organic revenue +14.5% |
| Gross profit / margin | $1,513.3 million / 51.0% | $1,305.7 million / 51.6% | Profit +15.9%; margin down 0.6 percentage points |
| Operating income / margin | $436.9 million / 14.7% | $432.7 million / 17.1% | Income +1.0%; margin down 2.4 points |
| Net income attributable to Bruker | $427.2 million | $296.6 million | +44.0% |
| Diluted EPS | $2.90 | $1.99 | +$0.91 |
| Cash from operations / capital expenditures | $350.1 million / $106.9 million | $274.4 million / $129.2 million | Free cash flow: $243.2 million vs. $145.2 million |
Revenue rose across all segments: BioSpin $798.5 million (+14.6%), CALID $960.4 million (+16.8%), Nano $941.9 million (+19.7%) and BEST $280.7 million (+18.4%). Management attributed growth to demand for differentiated instruments and solutions, pricing, and acquisitions. Currency effects added approximately $11.2 million to reported revenue, while acquisitions contributed $56.2 million.
GAAP operating income grew only modestly as higher gross profit was offset by increased selling, R&D and other costs. Non-GAAP operating margin was 18.4%, down from 20.0%; non-GAAP gross margin was 52.2%, down from 52.6%. These company-defined measures exclude specified costs, including restructuring, acquisition-related expenses and acquired-intangible amortization.
Liquidity, debt and capital allocation
- Cash and cash equivalents were $488.3 million at year-end, down from $645.5 million. The company reported $350.1 million of operating cash flow and a $157.1 million net decrease in cash, cash equivalents and restricted cash.
- Total debt, including finance leases, was $1,281.5 million, versus $1,219.2 million in 2022; $121.2 million was classified as current. The company reported $599.6 million available under its then-existing revolving facility and compliance with debt covenants at year-end.
- Current assets were $2,164.2 million and current liabilities $1,202.1 million. Cash, cash equivalents and short-term investments totaled $488.3 million; $398.4 million was held by foreign subsidiaries.
- Share repurchases totaled $152.3 million and dividends paid were $29.4 million. The 2023 repurchase authorization had $369.9 million remaining at year-end. The quarterly dividend was $0.05 per share in February 2024.
Material changes, outlook and unusual items
- PhenomeX acquisition: Bruker acquired PhenomeX in October 2023 for net consideration of $109.4 million and recorded a $144.1 million bargain-purchase gain, equal to $0.99 per share. The gain materially boosted reported earnings and reduced the effective tax rate to 21.6% from 28.1%. Purchase accounting, including acquired tax assets and NOLs, remained provisional; the filing says the final Section 382 analysis could change the gain. The acquired business reported $7.0 million revenue and a $43.4 million pretax loss from acquisition through year-end.
- Restructuring and other charges: Other charges, net were $52.2 million, up from $29.7 million. They included $18.8 million of restructuring costs, largely associated with PhenomeX, and $5.7 million of long-lived asset impairments. The BCA restructuring includes headcount reductions, facility consolidation and changes to product offerings; completion was expected in 2024.
- Backlog: Remaining performance obligations were approximately $2,226.7 million, versus $2,258.8 million a year earlier. Management cautions that backlog is not necessarily a reliable indicator of long-term revenue.
- Management outlook: Bruker expects existing cash and credit facilities, together with planned debt-note issuances and its amended credit agreement, to meet operating and investing needs for at least 12 months. Expected 2024 capital expenditures are approximately $125 million. The filing provides no specific 2024 revenue or earnings guidance.
- Subsequent financing and acquisition: In January 2024, Bruker increased its revolving credit facility from $600 million to $900 million and extended maturity to January 2029; it also borrowed CHF 230 million and repaid $100 million of 2012 notes. Planned CHF senior-note issuances totaling CHF 431 million were expected to close in April 2024. In February 2024, Bruker signed an agreement to acquire ELITechGroup for enterprise value of €870 million (approximately $962 million), subject to adjustments and closing conditions.
Risks and contingencies
- Supply shortages, longer lead times, inflation, higher energy and logistics costs, and limited-source suppliers could disrupt production, delay revenue and pressure margins. Management said 2023 price increases did not fully offset inflation.
- Demand depends in part on research spending and government, academic and customer budgets. International operations expose Bruker to currency, geopolitical, trade, regulatory and economic risks; non-U.S. operations represented approximately 74% of revenue.
- Competition and rapid technological change, acquisition integration, product acceptance, regulatory approvals and manufacturing concentration are significant business risks. Medical and in-vitro diagnostic products face evolving regulatory requirements, including EU IVDR recertification deadlines.
- Debt service, covenant compliance and the location of cash overseas may constrain flexibility. Unconditional purchase commitments totaled $410.9 million, mostly due in 2024.
- The company reported ordinary-course litigation and government inquiries, but no pending matters it believed were reasonably likely to have a material impact; no material contingency accruals were recorded. A related European patent application in a previously withdrawn Zeiss dispute remained pending, with its outcome uncertain.
- Auditors and management concluded internal control over financial reporting was effective at year-end. Certain 2023 acquisitions, representing approximately 9% of assets and 1% of revenue, were excluded from the control assessment and auditor attestation.
Investor verification priorities
- Assess underlying earnings and margins excluding the $144.1 million PhenomeX bargain-purchase gain, and review the provisional purchase accounting and acquired NOL limitations.
- Track BCA’s post-acquisition losses, restructuring execution, impairment risk and contribution to future segment performance.
- Reconcile debt, cash location, the 2024 borrowing and note issuances, covenant headroom, and funding for the proposed ELITechGroup acquisition.
- Monitor working capital, especially inventory, which increased to $968.3 million from $800.1 million, and whether backlog converts to revenue on schedule.
- Verify the timing and cost impact of supply constraints, inflation, foreign exchange, regulatory recertifications and the company’s $125 million 2024 capital-spending expectation.